Comparative In Vitro Susceptibility of Clinical Isolates of Candida parapsilosis Complex and Other Candida Species to Caspofungin and Anidulafungin by Etest

REFERENCES

• Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol 2009; 46: 212–29.
   PubMed Web of Science ®Google Scholar
• Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009; 43: 1647–57.
   PubMed Web of Science ®Google Scholar
• Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007; 3: 71–97.
   PubMedGoogle Scholar
• Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004; 23: 805–812.
   PubMed Web of Science ®Google Scholar
• Douglas CM, D'Ippolito JA, Shei GJ, Meinz M, Onishi J, Marrinan JA, et al. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997; 41: 2471–2479.
   PubMed Web of Science ®Google Scholar
• Pfaller MA. Anidulafungin: an echinocandin antifungal. Expert Opin Investig Drugs 2004; 13: 1183–1197.
   PubMed Web of Science ®Google Scholar
• Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA. Activities of micafungin against 315 invasive clinical isolates of flu-conazole-resistant Candida spp. J Clin Microbiol 2006; 44: 324–326.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical iso-lates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 5425-5427.
   Google Scholar
• Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr., Calandra TF, Edwards JE, Jr., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503–535.
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Spreghini E, Tomassetti S, Della Vittoria A, Arzeni D, Manso E, et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006; 50: 2719–2727.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149–3154.
   Google Scholar
• Ahmad S, Khan Z, Mustafa AS, Khan ZU. Seminested PCR for diag-nosis of candidemia: comparison with culture, antigen detection, and bio-chemical methods for species identification. J Clin Microbiol 2002; 40: 2483–2489.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Khan Z, Mokaddas E, Khan ZU. Isolation and molecular identification of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Kuwait. J Med Microbiol 2004; 53: 633–637.
   PubMed Web of Science ®Google Scholar
• Asadzadeh M, Ahmad S, Al-Sweih N, Khan ZU. Rapid molecular dif-ferentiation and genotypic heterogeneity among Candida parapsilosis and Candida orthopsilosis strains isolated from clinical specimens in Kuwait. J Med Microbiol 2009; 58: 745–752.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Canton E, Peman J, Martin-Mazuelo E. Compari-son of anidulafungin MICs determined by the clinical and laboratory stan-dards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. Antimicrob Agents Chemother 2010; 54: 1347–1350.
   PubMed Web of Science ®Google Scholar
• Barry AL, Pfaller MA, Brown SD, Espinel-Ingroff A, Ghannoum MA, Knapp C, et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol 2000; 38: 3457–3459.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard. CLSI M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA. 2008.
   Google Scholar
• Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and pro-posal for interpretive MIC breakpoints. J Clin Microbiol 2008; 46: 2620–2629.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, L. Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidu-lafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150–156.
   Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 1–53.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones RN. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J Clin Microbiol 2010; 48: 1592–1599.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010; 48: 52–56.
   PubMed Web of Science ®Google Scholar
• Desnos-Ollivier M, Dromer F, Dannaoui E. Detection of caspofungin resistance in Candida spp. by Etest. J. Clin. Microbiol 2008; 46: 2389–2392.
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Lortholary O, Raoux D, Bougnoux ME, Galeazzi G, Lawrence C, et al. Comparative in vitro activities of caspofungin and mica-fungin, determined using the method of the European Committee on An-timicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006. Antimicrob Agents Chemother 2008; 52: 778–781.
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A natu-rally occurring proline-to-alanine amino acid change in FIcslp in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 52: 2305–2312.
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA, RuhnIce M, Barrios C, Raghunadharao D, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369 (9572): 1519–1527.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ. et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883–893.
   PubMed Web of Science ®Google Scholar
• Arendrup M, Horn T, Frimodt-Moller N. In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection 2002; 30: 286–291.
   PubMed Web of Science ®Google Scholar
• Almirante B, Rodriguez D, Cuenca-Estrell M, Almela M, Sanchez F, Ayats J. et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006; 44: 1681–1685.
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472–2482.
   PubMed Web of Science ®Google Scholar
• Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In Vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 2010; 54: 2497–2506.
   PubMed Web of Science ®Google Scholar
• Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J. Infect. 2008; 56: 126–129.
   PubMed Web of Science ®Google Scholar
• Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-4752.
   Google Scholar
• Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexan-der. BD. Breakthrough Invasive Candidiasis on Micafungin. J. Clin. Micro-biol. April 26, 2010. doi:10.1128/JCM.02390-2309.
   Google Scholar
• Canton E, Espinel-Ingroff A, Pemán J, del Castillo L. In vitro fungi-cidal activities of echinocandins against Candida metapsilosis, C. orthop-silosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother 2010; 54: 2194–2197.
   PubMed Web of Science ®Google Scholar
• van Asbeck E, Clemons KV, Martinez M, Tong AJ, Stevens DA. Sig-nificant differences in drug susceptibility among species in the Candida para-psilosis group. Diagn Microbiol Infect Dis 2008; 62: 106–109.
   PubMed Web of Science ®Google Scholar